Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
In the developing pharma landscape, it’s important to consider all variables to create a winning portfolio strategy. To support the development of your own successful portfolio strategy, Pharma Intelligence invites you to watch our webinar: “Where is the pharma industry maximizing value?”, filmed on Tuesday May 23, 2017, presented by Datamonitor Healthcare Principal Analyst, Amanda Micklus.
This webinar focuses on the state of the pharma industry regarding long-term portfolio planning from the R&D stage through externalization and commercialization. Covered topics include:
Business development trends, including - internal R&D spending (including productivity measurements). What are the factors contributing to the projected sharp CAGR decline through 2020? Who shows most success with new product launches, and why?
Licensing and deal-making - How does pharma complement internal R&D with external business development deals? Find out by volume, value, phase, and therapy area.
Revenue trends – How do we view R&D investment and licensing/deal-making through the lens of revenue? Compare companies in Big Pharma, Mid Pharma, and Japan Pharma in terms of internal R&D product revenue versus that from external products.
Datamonitor Healthcare: data analysis and insight
14 Nov 2022
Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.
Datamonitor Healthcare: data analysis and insight
By Dominique Fontanilla 14 Nov 2022
There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.
Topics Cancer
Datamonitor Healthcare: data analysis and insight
14 Nov 2022
This essential whitepaper looks at how increased drug spending and a rising desire for expenditure controls are influencing access dynamics across key markets. It is available to you now, for free.
Request a Demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Speak to Sales
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Client Services
Contact us for product technical and account support.
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
